TD Asset Management’s Agios Pharmaceuticals AGIO Stock Holding History

TD Asset Management’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$560K	Sell	15,086 -8,646	-36%	-$262K	﹤0.01%	1164
2026 Q1	$803K	Sell	23,732 -33,560	-59%	-$951K	﹤0.01%	1120
2025 Q4	$1.56M	Sell	57,292 -71,002	-55%	-$2.49M	﹤0.01%	1034
2025 Q3	$5.15M	Sell	128,294 -39,900	-24%	-$1.5M	﹤0.01%	785
2025 Q2	$5.59M	Sell	168,194 -9,878	-6%	-$299K	﹤0.01%	754
2025 Q1	$5.22M	Buy	178,072 +12,400	+7%	+$411K	﹤0.01%	780
2024 Q4	$5.44M	Sell	165,672 -61,600	-27%	-$2.89M	﹤0.01%	782
2024 Q3	$10.4M	Buy	227,272 +16,800	+8%	+$763K	0.01%	635
2024 Q2	$9.08M	Buy	210,472 +54,054	+35%	+$1.95M	0.01%	636
2024 Q1	$4.57M	Buy	156,418 +64,200	+70%	+$1.72M	﹤0.01%	792
2023 Q4	$2.05M	Hold	92,218	–	–	﹤0.01%	999
2023 Q3	$2.28M	Buy	92,218 +43,719	+90%	+$1.16M	﹤0.01%	924
2023 Q2	$1.37M	Hold	48,499	–	–	﹤0.01%	1058
2023 Q1	$1.11M	Sell	48,499 -16,700	-26%	-$444K	﹤0.01%	1110
2022 Q4	$1.83M	Buy	65,199 +9,400	+17%	+$265K	﹤0.01%	1017
2022 Q3	$1.59M	Sell	55,799 -8,900	-14%	-$239K	﹤0.01%	1076
2022 Q2	$1.43M	Sell	64,699 -5,956	-8%	-$135K	﹤0.01%	1101
2022 Q1	$2.06M	Sell	70,655 -16,160	-19%	-$494K	﹤0.01%	1079
2021 Q4	$2.85M	Buy	86,815 +18,820	+28%	+$758K	﹤0.01%	1044
2021 Q3	$3.14M	Buy	67,995 +3,800	+6%	+$184K	﹤0.01%	955
2021 Q2	$3.09M	Sell	64,195 -1,889	-3%	-$106K	﹤0.01%	956
2021 Q1	$3.41M	Buy	66,084 +7,916	+14%	+$392K	﹤0.01%	936
2020 Q4	$2.52M	Sell	58,168 -4,100	-7%	-$162K	﹤0.01%	973
2020 Q3	$2.18M	Hold	62,268	–	–	﹤0.01%	884
2020 Q2	$3.33M	Buy	62,268 +16,800	+37%	+$778K	﹤0.01%	755
2020 Q1	$1.61M	Buy	45,468 +1,400	+3%	+$64.7K	﹤0.01%	877
2019 Q4	$2.1M	Sell	44,068 -1,800	-4%	-$68K	﹤0.01%	916
2019 Q3	$1.49M	Sell	45,868 -1,600	-3%	-$66.2K	﹤0.01%	980
2019 Q2	$2.37M	Sell	47,468 -5,200	-10%	-$278K	﹤0.01%	877
2019 Q1	$3.55M	Buy	52,668 +11,068	+27%	+$645K	0.01%	774
2018 Q4	$1.92M	Sell	41,600 -12,900	-24%	-$796K	﹤0.01%	919
2018 Q3	$4.2M	Sell	54,500 -1,000	-2%	-$80.4K	0.01%	784
2018 Q2	$4.67M	Sell	55,500 -2,900	-5%	-$253K	0.01%	724
2018 Q1	$4.78M	Buy	58,400 +23,557	+68%	+$1.82M	0.01%	680
2017 Q4	$1.99M	Buy	34,843 +1,043	+3%	+$65.6K	﹤0.01%	887
2017 Q3	$2.26M	Buy	33,800 +3,800	+13%	+$228K	﹤0.01%	840
2017 Q2	$1.54M	Buy	30,000 +1,400	+5%	+$71.6K	﹤0.01%	936
2017 Q1	$1.67M	Buy	28,600 +3,300	+13%	+$158K	﹤0.01%	926
2016 Q4	$1.06M	Buy	25,300 +4,700	+23%	+$247K	﹤0.01%	1012
2016 Q3	$1.09M	Buy	20,600 +7,400	+56%	+$322K	﹤0.01%	989
2016 Q2	$553K	Buy	+13,200	New	+$652K	﹤0.01%	1085
2015 Q4	–	Sell	-2,900	Closed	-$205K	–	1356
2015 Q3	$205K	Hold	2,900	–	–	﹤0.01%	1297
2015 Q2	$322K	Hold	2,900	–	–	﹤0.01%	1238
2015 Q1	$273K	Buy	2,900 +200	+7%	+$22.4K	﹤0.01%	1269
2014 Q4	$303K	Buy	+2,700	New	+$241K	﹤0.01%	1228

Other funds holding AGIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TD Asset Management's AGIO Position: Q2 2026 in Review

TD Asset Management reduced its Agios Pharmaceuticals (AGIO) stake by 36% in Q2 2026, selling an estimated $262K and leaving 15,086 shares worth $560K. The position accounts for ﹤0.01% of the portfolio, ranked #1164.

TD Asset Management first reported a position in AGIO in Q4 2014 and has held it in 45 quarters since. The position peaked at $10.4M in Q3 2024. 157 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

TD Asset Management held 15,086 shares of Agios Pharmaceuticals worth $560K as of Q2 2026.
TD Asset Management sold 8,646 Agios Pharmaceuticals shares in Q2 2026, an estimated $262K.
Agios Pharmaceuticals made up ﹤0.01% of TD Asset Management's portfolio in Q2 2026, its #1164 holding.
TD Asset Management first reported a position in Agios Pharmaceuticals in Q4 2014 and has held it in 45 quarters since.
TD Asset Management's Agios Pharmaceuticals position peaked at $10.4M in Q3 2024.
157 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.